GI
ALXN

GLG Inc’s Alexion Pharmaceuticals ALXN Stock Holding History

GLG Inc’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		$2.81M Hold
21,087
– – 0.07% 299
2013
Q3 		$2.45M Hold
21,087
– – 0.05% 393
2013
Q2 		$1.95M Buy
+21,087
New +$2.03M 0.05% 312

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GLG Inc's ALXN Position: Q4 2013 in Review

GLG Inc held its Alexion Pharmaceuticals (ALXN) position steady in Q4 2013 at 21,087 shares worth $2.81M. The position accounts for 0.07% of the portfolio, ranked #299.

GLG Inc first reported a position in ALXN in Q2 2013 and has held it in 3 quarters since. 462 funds tracked by Wall St. Rank hold ALXN as of Q4 2013.

  • GLG Inc held 21,087 shares of Alexion Pharmaceuticals worth $2.81M as of Q4 2013.
  • GLG Inc left its Alexion Pharmaceuticals share count unchanged in Q4 2013.
  • Alexion Pharmaceuticals made up 0.07% of GLG Inc's portfolio in Q4 2013, its #299 holding.
  • GLG Inc first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 3 quarters since.
  • 462 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2013.

Based on GLG Inc's 13F filing for Q4 2013, filed 14 Feb 2014.